Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because of their many advantages, researchers investigate the therapeutic potential of single domain antibodies.
Download this poster from The Scientist’s Creative Services Team to learn about
- The differences between monoclonal, camelid heavy chain, and single domain antibodies
- How scientists improve the delivery and efficacy of VHH antibody-based therapies
- Examples of existing VHH antibody-based therapeutics used to treat cancer, autoimmune disorders, and infectious diseases
